<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264626</url>
  </required_header>
  <id_info>
    <org_study_id>116/2014O</org_study_id>
    <nct_id>NCT02264626</nct_id>
  </id_info>
  <brief_title>Sedation During Noninvasive Ventilation (NIV)</brief_title>
  <acronym>REMI</acronym>
  <official_title>Effects of Remifentanil Based Sedation on Patient-ventilator Interaction, in Patients Undergoing Noninvasive Ventilation (NIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients undergoing NIV for acute respiratory, lack of tolerance is one of the main reason
      of failure.

      This may result in a poor synchrony between the patient and the machine, leading to gross
      mismatching and potentially to an increased work of breathing.

      The investigators aim to investigate whether in these patients poorly responding to NIV the
      use of a sedation protocol using remifentanil will lead to an improve patient-ventilator
      interaction and better compliance to NIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients undergoing NIV for acute respiratory, lack of tolerance is one of the main reason
      of failure.

      This may result in a poor synchrony between the patient and the machine, leading to gross
      mismatching and potentially to an increased work of breathing.

      The investigators aim to investigate whether in these patients poorly responding to NIV the
      use of a sedation protocol using remifentanil will lead to an improve patient-ventilator
      interaction and better compliance to NIV.

      In this physiological study the investigators will study 15 patients at risk of failing NIV
      because of scarce tolerance and showing clinical signs of poor interaction with the
      ventilator.

      Once the patient will be enrolled the investigators will record using the balloon-catheter
      technique the online measurement of respiratory mechanics, to assess the inspiratory muscle
      effort and the matching between the patient breathing pattern and that of the ventilator The
      investigators will also record the clinical success of sedation (i.e. need or not for
      endotracheal intubation)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient-ventilator interaction</measure>
    <time_frame>one hour</time_frame>
    <description>patient-ventilator interaction will be assessed using the recording of respiratory mechanics to identify</description>
  </primary_outcome>
  <primary_outcome>
    <measure>matching of inspiratory timing</measure>
    <time_frame>one hour</time_frame>
    <description>the patients inspiratory time vs ventilator inspiratory time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wasted efforts</measure>
    <time_frame>one hour</time_frame>
    <description>breaths unable to trigger the ventilator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIV failure</measure>
    <time_frame>one hour</time_frame>
    <description>failure will be defined as the need for intubation:
gasping for air
worsening of sensorium
respiratory arrest
retention of secretions and/ or death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Hypercapnic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>acutely ill patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of remifentanil at the infusion rate by 0.025 μg kg-1 min-1 to a maximum of 0.10 μg kg-1 min-1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.</description>
    <arm_group_label>acutely ill patients</arm_group_label>
    <other_name>ultriva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ph&lt;7,35 and PaCO2&gt;50 mmHg with acute respiratory failure

          -  Signs of respiratory distress and poor synchrony with the ventilator as assessed on
             the ventilator screen and by looking patient own rate and ventilator recorded rate

        Exclusion Criteria:

          -  Patients responding well to NIV and not showing signs of poor synchrony
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stefano nava, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>sant'orsola hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>stefano nava, md</last_name>
    <phone>393333751828</phone>
  </overall_contact>
  <location>
    <facility>
      <name>San'Orsola Malpighi Hospital, Bologna ITALY</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Nava, MD</last_name>
      <phone>051 6364017</phone>
      <email>stefano.nava@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Nava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>October 8, 2016</last_update_submitted>
  <last_update_submitted_qc>October 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>dr. Stefano Nava</investigator_full_name>
    <investigator_title>Professor of Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>acute respiratory failure</keyword>
  <keyword>noninvasive ventilation</keyword>
  <keyword>sedation</keyword>
  <keyword>patient/ventilator interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

